As congressional leaders prepare to lock themselves away and hammer out a final tax bill, one thing is clear: Big Pharma, like the rest of corporate America, is going to get a big break.
But there are devilish details the drug industry will be tracking, including the fates of an oft-used tax credit and a long-promised provision that would make it cheaper for multinational companies to bring overseas cash back to the U.S.
About the Author Reprints
